| 000 | 01790cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030821.0 | ||
| 008 | 130410s2012 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.07.M.Sc.2012.Sa.M | ||
| 100 | 0 | _aSafa Nabil Abdelfattah Mohamed | |
| 245 | 1 | 0 |
_aMdm2 and p53 codon 72 polymorphisms in acute myeloid leukemia / _cSafa Nabil Abdelfattah Mohamed ; Supervised Nabil Mohsen Eldanasouri , Shadia Hassan Ragab , Zainab Ali Hassan Elsaadany |
| 246 | 1 | 5 | _aفى حالات سرطان الدم الميلودى الحادP53 وشفرة 72 للجينMDM2 المظاهرة المتعددة للجين |
| 260 |
_aCairo : _bSafa Nabil Abdelfattah Mohamed , _c2012 |
||
| 300 |
_a200P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology | ||
| 520 | _aAcute myeloid leukemia (AML) is a heterogeneous disease with numerous genetic abnormalities . Among them , functional SNPs in both , the tumor suppressor protein , p53 and its key cellular regulator Mdm2 . We investigated the risk of Mdm 2 SNP309 alone or in combination with the p53 codon 72 polymorphism in AML patients in a study that included 50 de novo AML patients and 50 healthy control subjects | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAcute myeloid leukemia | |
| 653 | 4 | _aMdm2 | |
| 653 | 4 | _aP53 | |
| 700 | 0 |
_aNabil Mohsen Eldanasouri , _eSupervisor |
|
| 700 | 0 |
_aShadia Hassan Ragab , _eSupervisor |
|
| 700 | 0 |
_aZainab Ali Hassan Elsaadany , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c42565 _d42565 |
||